BioSpace News Archive

The global gene therapy market size was valued at USD 8.75 billion in 2023 and is poised to grow from USD 10.47 billion in 2024

Bayer is recalling two lots of hydraSense® Baby Nasal Care Easydose® due to a potential contamination.

Sight Sciences, Inc. announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024.

The global cancer gene therapy market size was accounted for USD 2.95 billion in 2023 and it is increasing around USD 18.11 billion by 2033

Partner Therapeutics, Inc. announced publication of a comprehensive review by Dougan et al. in Cancers summarizing the mechanistic rationale and pre-clinical and clinical data regarding the use of Leukine to manage gastrointestinal immune-related adverse events for patients taking immune checkpoint inhibitors for the treatment of cancer.

Celularity Inc. (Nasdaq: CELU) (“Celularity”) today announced that its abstract entitled “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.

Evolent Health, Inc. (NYSE: EVH) today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced it will be presenting promising new preclinical data from its platform built to discover treatments for serious skin diseases at three upcoming scientific and medical conferences.

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.